DRI-C25441

DRI-C25441 is a potent blocker of CD40 and CD40L interaction, with an IC50 of 0.36 μM. DRI-C25441 can inhibit the immune response induced by alloantigen. can inhibit CD40L induced activation of NF-κB signaling pathway. DRI-C25441 commonly is used in research on immune conditions [1][2].

Product Specifications

CAS Number

[2101765-83-5]

UNSPSC

12352005

Target

NF-κB; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/dri-c25441.html

Purity

99.53

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=C2C=CC=CC2=C(NC(C3=CC=C(C4=CC=C(NC(C5=CC=C([N+]([O-])=O)C=C5)=O)C=C4)C=C3)=O)C=C1)O

Molecular Formula

C31H21N3O6

Molecular Weight

531.51

References & Citations

[1]Lu H, et, al. Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. Signal Transduct Target Ther. 2020 Sep 23;5 (1) :213. |[2]Chen J, et al. Small-Molecule Inhibitors of the CD40-CD40L Costimulatory Protein-Protein Interaction. J Med Chem. 2017 Nov 9;60 (21) :8906-8922.